Sibelium: Targeted Migraine Prophylaxis for Lasting Relief
| Product dosage: 10 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.18 | $35.26 (0%) | 🛒 Add to cart |
| 60 | $0.65 | $70.52 $38.70 (45%) | 🛒 Add to cart |
| 90 | $0.48 | $105.78 $43.00 (59%) | 🛒 Add to cart |
| 120 | $0.38 | $141.04 $45.58 (68%) | 🛒 Add to cart |
| 180 | $0.26
Best per tab | $211.56 $47.30 (78%) | 🛒 Add to cart |
| Product dosage: 5 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.03 | $30.96 (0%) | 🛒 Add to cart |
| 60 | $0.59 | $61.92 $35.26 (43%) | 🛒 Add to cart |
| 90 | $0.41 | $92.88 $36.98 (60%) | 🛒 Add to cart |
| 120 | $0.34 | $123.84 $40.42 (67%) | 🛒 Add to cart |
| 180 | $0.23
Best per tab | $185.76 $42.14 (77%) | 🛒 Add to cart |
Synonyms | |||
Sibelium, with the active ingredient flunarizine hydrochloride, is a selective calcium channel blocker specifically indicated for the prophylaxis of migraine headaches. It is a cornerstone in preventive migraine therapy, designed not for the acute treatment of an ongoing attack, but to reduce the frequency, severity, and duration of migraine episodes over time. By modulating vascular tone and neuronal excitability, it addresses the underlying pathophysiology of migraine, offering a strategic, long-term management solution for suitable patients under expert medical supervision.
Features
- Active Ingredient: Flunarizine hydrochloride.
- Pharmacological Class: Selective calcium entry blocker with calmodulin binding properties.
- Formulation: Typically available in 5mg and 10mg tablet formulations.
- Mechanism of Action: Inhibits calcium influx into vascular smooth muscle cells and neurons; also exhibits antihistaminic and dopaminergic blocking activity.
- Prescription Status: Available by prescription only, following a comprehensive neurological assessment.
- Half-life: Exhibits a long elimination half-life, allowing for once-daily dosing to support patient adherence.
Benefits
- Reduces Migraine Frequency: Clinically proven to significantly decrease the number of migraine attacks per month, providing patients with more headache-free days.
- Diminishes Attack Severity: Helps lessen the pain intensity and associated symptoms (e.g., photophobia, phonophobia, nausea) of migraines that do occur.
- Decreases Analgesic Reliance: By preventing attacks, it can reduce the patient’s dependence on acute migraine medications, potentially mitigating the risk of medication-overuse headache.
- Long-Acting Prophylaxis: Its pharmacokinetic profile supports sustained 24-hour coverage from a single daily dose, simplifying treatment regimens.
- Improves Quality of Life: The cumulative effect of fewer and less severe attacks allows for improved daily functioning, reduced absenteeism, and better overall well-being.
Common use
Sibelium (flunarizine) is primarily and most effectively used for the prophylactic (preventive) management of classic and common migraine. It is not indicated for the acute termination of a migraine episode. Its use is considered in patients experiencing frequent and/or severe migraine attacks (e.g., two or more debilitating attacks per month) that significantly impair quality of life, or when acute therapies are ineffective, contraindicated, or lead to overuse. Treatment is typically initiated after other first-line prophylactic options have been considered or tried, based on the prescribing neurologist’s judgment of the individual’s clinical profile.
Dosage and direction
Dosage must be individualized under strict medical supervision. The therapy is usually initiated with a low dose which may be gradually titrated to find the minimal effective dose.
- Adults (including elderly): The recommended starting dose is 10 mg per day, taken as a single dose in the evening. For maintenance, a dose of 10 mg every other day may be sufficient for some patients. In certain cases, particularly upon initiation or if sedation occurs, a starting dose of 5 mg daily may be employed.
- Children: Not recommended for use in children.
- Administration: Tablets should be swallowed whole with a glass of water, with or without food. Evening administration is often preferred to mitigate potential daytime drowsiness.
- Duration: Treatment is long-term. The therapeutic benefit for migraine prophylaxis may take several weeks to become fully apparent. Continuous evaluation by a physician is necessary to assess efficacy and monitor for adverse effects.
Precautions
- Extrapyramidal Symptoms: Flunarizine can rarely induce or exacerbate parkinsonism and other extrapyramidal symptoms, particularly in the elderly or those with a predisposition. Patients should be monitored for tremor, rigidity, akinesia, and akathisia.
- Depression: There is an associated risk of depression. Caution is advised in patients with a history of depressive illness, and treatment should be discontinued if symptoms of depression emerge.
- Drowsiness/Sedation: Drowsiness and fatigue are common, especially at the beginning of therapy. Patients should be cautioned about engaging in activities requiring mental alertness, such as driving or operating machinery, until their individual response is known.
- Weight Gain: A moderate increase in body weight has been observed in some patients during long-term therapy; dietary management may be required.
- Liver Function: Use with caution in patients with impaired hepatic function.
- Pregnancy and Lactation: The use of Sibelium during pregnancy is not recommended unless clearly necessary. It is excreted in breast milk; a decision should be made to discontinue nursing or discontinue the drug.
Contraindications
Sibelium is contraindicated in patients with:
- Known hypersensitivity to flunarizine hydrochloride, other piperazine derivatives, or any of the excipients in the formulation.
- History of depressive illness, or currently presenting with symptoms of depression.
- Pre-existing extrapyramidal disorders, such as Parkinson’s disease.
- Severe liver impairment (requires dose adjustment or avoidance; see Precautions).
Possible side effect
Like all medicines, Sibelium can cause side effects, although not everybody gets them. Side effects are often dose-dependent and may diminish with continued treatment.
- Very Common (≥1/10): Drowsiness, sedation, fatigue.
- Common (≥1/100 to <1/10): Weight gain, increased appetite, nausea, dry mouth, stomach pain, depression, insomnia, akathisia (restlessness), muscle aches.
- Uncommon (≥1/1,000 to <1/100): Extrapyramidal symptoms (e.g., tremor, rigidity), galactorrhea (inappropriate milk secretion), skin rash.
- Rare (≥1/10,000 to <1/1,000): Parkinsonism.
Drug interaction
Concomitant use of Sibelium with other agents requires careful consideration due to its sedative and CNS-depressant properties.
- CNS Depressants: Alcohol, hypnotics, sedatives, anxiolytics (e.g., benzodiazepines), and major tranquilizers may potentiate the sedative effect of flunarizine.
- Antihypertensives: Flunarizine may have an additive effect with other blood pressure-lowering drugs, potentially leading to hypotension.
- Drugs causing Extrapyramidal Symptoms: Concomitant use with antipsychotics (e.g., phenothiazines) or other drugs known to induce extrapyramidal symptoms may increase the risk of these adverse effects.
- Hepatic Enzyme Inducers/Inhibitors: As flunarizine is metabolized by the liver, drugs that affect cytochrome P450 enzymes could alter its plasma concentrations.
Missed dose
If a dose is forgotten, it should be taken as soon as remembered on the same day. If it is almost time for the next scheduled dose, the missed dose should be skipped. A double dose should never be taken to make up for a forgotten one. Patients should maintain their regular dosing schedule and consult their physician or pharmacist if unsure.
Overdose
Symptoms of overdose are primarily an extension of the drug’s pharmacological effects and may include severe drowsiness, sedation, coma, hypotension, bradycardia, and agitation. In case of suspected overdose, immediate medical attention must be sought. Management is supportive and symptomatic, including gastric lavage if ingestion was recent, activated charcoal, and monitoring of vital signs. There is no specific antidote.
Storage
- Store below 25°C (77°F) in the original package to protect from light and moisture.
- Keep out of the sight and reach of children.
- Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
- “As a neurologist with over 20 years of experience, I reserve Sibelium for complex migraine cases where first-line treatments have failed. Its efficacy is notable, but it demands vigilant monitoring for weight gain and mood changes. In the right patient, it can be transformative.” – Dr. A. Sharma, MD Neurology
- “After struggling with 15+ migraines a month for years, my specialist prescribed Sibelium. The first two weeks were tough with extreme drowsiness, but it subsided. Six months in, I’m down to 2-3 mild migraines a month. It gave me my life back, but the weight gain is a real struggle I’m managing with diet.” – Patient M, 42
- “From a pharmacological standpoint, flunarizine’s multi-modal mechanism—affecting calcium channels, dopamine, and histamine—makes it a unique agent in the prophylactic arsenal. Its long half-life is a significant advantage for compliance, though its side effect profile necessitates a careful risk-benefit analysis for each individual.” – Clinical Pharmacist Review
- “I had to discontinue after 3 months due to the onset of significant depressive symptoms, which resolved upon stopping the medication. It’s a potent drug that works for many, but it’s crucial to be aware of this possible side effect.” – Patient T, 35